Strongbridge Biopharma plc to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
About Strongbridge Biopharma
Strongbridge Biopharma is a commercial-stage global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts: Corporate and Media Relations Elixir Health Public RelationsLindsay Rocco +1 862-596-1304 [email protected] Investor Relations U.S.:The Trout Group Marcy Nanus +1 646-378-2927 [email protected]Europe : First House Mitra Hagen Negård +47 21 04 62 19 [email protected]USA 900 Northbrook Drive Suite 200Trevose , PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389